Table 3 Summary of cost and clinical parameters
Authors/ year | Cost of G-CSF (per cycle) | FN hospitalization cost per day | FN baseline risk (%) | FN mortality risk (%) | FN RR of pegfilgrastima | Survival benefit of pegfilgrastim | Source of efficacy |
|---|---|---|---|---|---|---|---|
Fust et al. 2017 [23] | PP of filgrastim = £ 18,170 (6 days) and £8862 (11 days), pegfligrastim = £ 19,149 | US$ 7183 | 21 | 5.8 | 0.66 (11 days) 0.41 (6 days) | Yes | Meta-analysis |
Ravangard et al.2017 [33] | Pegfilgrastim = US$ 5299, filgrastim = US$ 4959 (3 days), filgrastim = US$ 5808 per dose | Not specified | Not specified | Not specified | Not specified | Not specified | Primary data |
Wang et al. 2016 [24] | Pegfilgrastim = US$ 532 per dose, filgrastim =300 μg per dose = US$ 352 (7 days) | Pegfilgrastim = US$ 22,135 filgrastim = US$ 9588 | 41.8 | NR | 0.89 | No | RCT |
Lathia et al. 2013 [19] | Pegfilgrastim 6 mg = CAN$ 2422, filgrastim 300 μg per dose = CAN$ 1740 (10 days) | CAN$ 1012 | 64 | NR | 0.58 | No | Meta-analysis |
Perrier et al.2013 [32] | Pegfilgrastim = US$ 25,024, filgrastim = US$ 28,700 |  | Not specified | Not specified | Not specified | Not specified | RCT |
Sebban et al.2012 [31] | Pegfilgrastim = US$ 23,256, filgrastim = US$ 25,448 | Pegfilgrastim = US$ 20,725,filgrastim = US$ 22,236 | 97.4 | Not specified | Not specified | Not specified | RCT |
Whyte et al. 2011 [21] | Filgrastim = £ 470 (6 days) and £ 862 (11 days), pegfligrastim = £ 686 | £ 235 | 17 for age 63 years 45 at age 72 years | 8.9 | 0.53 | Yes | Systematic review |
Lyman et al. 2009 [22] | Pegfilgrastim = US$ 2142, filgrastim = US$ 1596 (6 days) | US$ 15,921 | 27.9 | 5.8 | 0.52 | Yes | Literature review |